Cargando…

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens

INTRODUCTION: Recent single-site studies and case reports have linked atazanavir (ATV) with the occurrence of nephrolithiasis. The purpose of this study was to estimate and compare the incidence rate of nephrolithiasis and to characterize the occurrence of subsequent renal failure among patients on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nkhoma, Ella, Kumar, Monica, Hines, Patricia, Moorthy, Vidya, Klauck, Isabelle, Villasis Keever, Angelina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P028
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224927/ https://www.ncbi.nlm.nih.gov/pubmed/25394067 http://dx.doi.org/10.7448/IAS.17.4.19560

Ejemplares similares

SAVES US: Suppression of Airborne Viral Epidemic Spread by Ultraviolet light barriers
por: GARZELLA, Francesco, et al.
Publicado: (2023)

Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens
por: Nkhoma, Ella T., et al.
Publicado: (2016)

DETECÇÃO DE SARS-COV-2 EM ÁGUAS RESIDUÁRIAS COMO FERRAMENTA DE PREDIÇÃO DE INFECTADOS DE UMA CAPITAL DA REGIÃO CENTRO-OESTE DO BRASIL
por: de Sousa, Adriano Roberto Vieira, et al.
Publicado: (2022)

PRESSÃO SELETIVA E IMPACTO NA RESISTÊNCIA A CEFTAZIDIMA/AVIBACTAM NO MUNDO REAL
por: Filho, Daniel Freire de Figueirêdo, et al.
Publicado: (2022)

Impact du confinement dû au COVID-19 sur la prise en charge et le contrôle de l’artérite à cellules géantes
por: Praliaud, R., et al.
Publicado: (2020)

Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
por: Peng, Siyang, et al.
Publicado: (2014)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2012)

SERPINA1 PiZ and PiS Heterozygotes and Lung Function Decline in the SAPALDIA Cohort
por: Thun, Gian-Andri, et al.
Publicado: (2012)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
por: Scherrer, Alexandra U., et al.
Publicado: (2013)

Evaluation of disability in patients exposed to fluoroquinolones
por: Wilcox, Marsha A., et al.
Publicado: (2020)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

A survey of new PIs in the UK
por: Acton, Sophie E, et al.
Publicado: (2019)

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data
por: Nkhoma, Ella T., et al.
Publicado: (2016)

Who gets single tablet regimens (STR), and why?
por: Tarrier, Laura, et al.
Publicado: (2014)

DPM PERFORMANCE TESTING USING RASPBERRY PIS
por: Regala, M
Publicado: (2013)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Patients’ willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands
por: Engelhard, Esther, et al.
Publicado: (2014)

Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
por: Maria Bottani, Giulia, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Magnetic measurements on PIS MH 42 Lead ion
por: Borburgh, J
Publicado: (1995)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vihh3fdviac58sqkn4ik5d04ka